Effects of Smoking on Network Connectivity in Patients With Schizophrenia Symptoms in Scz Patients
Recruiting
N/A
Interventional Study
Smoking Cessation
Schizophenia Disorder
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 90 (estimated)
- Sponsor
- The Hong Kong Polytechnic University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The prevalence of smoking among people with schizophrenia (SCZ) is substantially higher at 54% to 90% (McClave et al., 2010). About half of all deaths amongst people with scz are attributed to smoking-related diseases and cancer involving the lung, the cardiovascular system, and the liver (Kely et al., 2011; WHO, 2019). Acceptance and commitment therapy (ACT) is effective for treating psychotic sy…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Individuals who have been diagnosed with schizophrenia or schizoaffective disorder and after at least one-year followup;
* currently taking anti-psychotic medications for ≥ 3 months with good compliance;
* aged 18 years or above;
* able to communicate in Cantonese
Exclusion C…
Contacts